News
2d
Investor's Business Daily on MSNHeart Drug Stock Rockets 20% On Sales, Boosts Outlook; Regeneron Pharma's Global Partnership Strong TailwindKiniksa stock rocketed 20% after first-quarter results on April 29. The biotech stock then broke out of a cup base with a buy ...
The Inflation Reduction Act includes an exemption for orphan drugs for a single indication, but experts say this is far from ...
Rett syndrome is a devastating rare genetic childhood disorder primarily affecting girls. Merely 1 out of 10,000 girls are ...
Hemispherian’s GLIX1 to treat malignant glioma receives US FDA orphan drug designation: Oslo, Norway Thursday, July 3, 2025, 15:00 Hrs [IST] Hemispherian AS, an Oslo-based pharm ...
The Orphan Cures Act has been added back into the Senate version of President Donald Trump’s “big, beautiful bill” after being ...
Paris: Sanofi has received orphan drug designation from the Ministry of Health, Labour and Welfare (MHLW) in Japan for ...
ABBV-706 is an ADC targeting SEZ6 developed by AbbVie. It is linked to a topoisomerase 1 inhibitor (TOP1i) via a ...
Sanofi (ENXTPA:SAN) recently received orphan drug designation from Japan's Ministry of Health for riliprubart, aimed at treating chronic inflammatory demyelinating polyneuropathy. This underscores the ...
The pharmaceutical industry’s lobbying muscle scored a high-stakes victory on Monday when the Senate parliamentarian reversed a previous decision and ruled that the Optimizing Research Progress Hope ...
Riliprubart granted orphan drug designation in Japan for chronic inflammatory demyelinating polyneuropathy. Two phase 3 studies are currently underway testing riliprubart in peopl ...
Japanese MHLW grants orphan drug designation to Sanofi’s riliprubart for chronic inflammatory demyelinating polyneuropathy: Paris Tuesday, July 1, 2025, 09:00 Hrs [IST] The Mini ...
7 years of market exclusivity in the U.S. upon FDA approval ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results